Background: A combination of tissue engineering methods employing mesenchymal
| INTRODUCTION
Osteoarthritis (OA) is a multifactorial condition of diverse aetiology that affects all tissues in synovial joints and culminates in structural and functional joint 'organ' failure, including loss and erosion of articular cartilage, subchondral bone remodelling, synovial inflammation and osteophyte formation. 1, 2 OA is the most common chronic articular disorder and affects most mammalian species, including humans, horses, dogs, cats and sheep, all of which exhibit a similar pathogenesis. [3] [4] [5] [6] [7] The pathophysiological events start with the degradation of extracellular matrix components of the articular cartilage either as a result of accumulated repetitive micro-damage, a major traumatic event, or metabolic and biochemical factors, and are driven principally by an early innate immune response that progressively catalyses degenerative changes. 1, 8 The disease process is difficult to interrupt and results in a vicious circle of inflammation and degradation, leading to a gradual loss of joint function and pain.
A number of putative mediators, including proteases, proinflammatory cytokines, growth factors and radicals, are implicated in the process, although pro-inflammatory cytokines appear to play a dominant role in the initiation and progression of articular cartilage destruction by disturbing the dynamic articular equilibrium between anabolic and catabolic processes. [9] [10] [11] [12] [13] [14] Interleukin (IL)-1β is one of the key arthritogenic triggers because it is much more potent than tumor necrosis factor (TNF)α with respect to inducing cartilage destruction, requiring only 0.1-1.0% of the TNFα dose to achieve the same proteoglycan synthesis inhibition in chondrocytes. 15 In joints, IL-1β is synthesized by chondrocytes, osteoblasts, synoviocytes and mononuclear cells and exerts its effect via binding to membrane receptor IL-1 receptor (IL-1R)1, whereas binding to IL-1R2 forms an inactive ligandreceptor complex that is unable to activate the intracellular signal. 14, [16] [17] [18] [19] Both, IL-1R1 and IL-1R2 also bind IL-1α and IL-1R
antagonist (IL-1Ra). In OA, there are increased levels of IL-1β in the synovial fluid, synovial membrane, cartilage and the subchondral bone layer and, furthermore, the expression of IL-1R1 on the surface of chondrocytes and synoviocytes is also increased. [20] [21] [22] in chondrocytes via upregulation of the Bcl-2 protein family members, mitochondrial depolarization, reactive oxygen species production and dysregulation of enzymatic antioxidant defenses in chondrocytes. [30] [31] [32] Damaged articular cartilage has little or no healing capacity because it is hypocellular, avascular, aneural and alymphatic, has a dense ECM that limits the migration capacity of the sparse population of chondrocytes, and has low metabolic activity. 3, 33 Hence, once damage has occurred, cartilage lesions are likely to progress.
Current treatment strategies are only symptom modifying, leaving a large unmet need for efficacious disease-modifying therapies, which has resulted in a growing interest in regenerative medicine approaches to OA. Based on our increasing understanding of the signalling pathways and key molecules interacting in the cascade of joint homeostasis and the pathophysiological processes involved in the development of OA, inflammatory mediators represent promising potential targets for therapeutic interventions designed to reduce both symptoms and structural joint damage in OA. [34] [35] [36] [37] [38] Given the pivotal role of IL-1 as a pro-inflammatory cytokine in the development of OA, its natural opponent IL-1Ra has been investigated in OA treatment.
39-42
In vitro and animal models of IL-1 inhibition by IL-1Ra showed a reduction of cartilage destruction associated with this therapy. 33 Commercially available kits that produce autologous conditioned serum containing an upregulated higher amount of IL-1Ra compared to the concentration found in unprocessed blood samples are available for humans, horses and dogs. However, multiple joint injections are recommended to achieve clinically meaningful results. 41, 43 Therapeutic intervention to limit articular cartilage damage is likely most efficient early in disease progression when there is a possibility of preserving or re-establishing articular homeostasis and enabling anabolic activity to balance the catabolic pathways activated by inflammatory mediators. 44 However, even in established OA, modulation of the articular microenvironment could significantly contribute to the treatment success.
Gene therapy is able to deliver a therapeutic gene to the target tissue ensuring a more constant and longer lasting therapeutic effect without the need of frequently repeated invasive articular injections.
Gene therapy applications to treat OA or rheumatoid arthritis have been published showing promising results. 8, [45] [46] [47] To interfere with joint homeostasis only when needed, an adjustable gene therapy is an attractive approach for fine-tuning any potential genetic treatment. 46 Inflammation inducible promoters have shown their great value in the context of tunable gene therapy. Such disease-(inflammation) responsive promoters will be 'switched on' only when pro-inflammatory cytokines are present, and will be silent again once the joint flair has been successfully treated. [48] [49] [50] In these cases, stimulation of the regulatory elements to enhance transgene expression from the outside would not be needed as is the need with tetracycline responsive promoter systems. 51 Indeed, the OA-affected joint would initiate the expression of the therapeutic gene and hence treatment when IL-1β
and TNFα are upregulated in the stage of inflammation. Recombinant lentivirus particles were produced and the respective titre was estimated as described previously. 49 MSCs were isolated from bone marrow collected from the iliac crest of a 3-year old male horse euthanized for reasons not related to the present study. MSCs were cultured as described previously. 49 MSCs were collected in accordance with the 'Good Scientific Practice. Two different cell densities were tested with regard to the planed short term (IL-1Ra induction, decline after cytokine withdrawal) and long- at the time of supernatant harvesting and the IL-1Ra protein production from 10 000 cells within 48 h was calculated (normalized production).
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For analysis of IL-Ra decline after cytokine withdrawal, 6 × 10 3 MSC/IL-1Ra cells were seeded per well into a 96-well plate. After 24 h, cells were stimulated with 10 ng/ml TNFα for 48 h and, subsequently, the medium was changed every day. After 2, 4 and 6 days, the IL-1Ra protein concentration was measured and relative IL-1Ra production was calculated as described above. RT-qPCR primer were designed using the PrimerQuest assay design tool (http: //eu.idtdna.com/PrimerQuest/Home/Index; Integrated DNA Technologies, Coralville, IA, USA) or taken from the literature. 60, 61 Assay details are provided in Cells were frozen after first passage and used in the experiments no later than in passage 3.
To set up the two-dimensional (2D) OA in vitro model, 2 × 10 In a second approach, chondrocytes were pre-treated with conditioned medium for 24 h and subsequently treated with 10 ng/ml IL-1β. After 
| Statistical analysis
For statistical analysis of the IL-1RA protein concentration measured via ELISA, as well as mRNA expression of OA-related genes assessed by RT-qPCR, the results of the respective control groups were arbitrary set to 1 and a relative increase or decrease was computed (as the fold change). Mean values and 95% confidence intervals were calculated from the technical replicates. Lower confidence limits greater than 1 (i.e. increase) and upper confidence limits less than 1 (i.e. decrease) were assumed to be significant. 
| Induction of IL-1Ra expression in transduced equine MSCs
Inducibility of the IL-1Ra protein production was measured in the supernatant of MSC/IL-1Ra cells stimulated for 48 h with different concentrations of IL-1β or TNFα using species-specific ELISA. In nonstimulated MSC/IL-1Ra cells, basal IL-1Ra protein levels (7.3 and 13.9 ng/ml/48 h for 3 × 10 3 and 6 × 10 3 cells seeded) were detected as a result of the presence of minimal CMV promoter sequences in the synthetic NF-κB-inducible promoter. As expected, TNFα induced IL-1Ra protein expression in a dose-dependent manner ( Figure 1A ).
An up to five-fold increase in IL-1Ra production was observed in cells stimulated with 10 ng/ml TNFα. Interestingly, no changes in IL-1Ra protein production were observed upon IL-1β stimulation ( Figure 1A) .
Therefore, the subsequent induction experiments were performed using TNFα only. The cell seeding density influenced the absolute IL-1-Ra protein production over the definite period of time; however, the relative changes (fold-changes) remained constant irrespective of the cell amount seeded ( Figure 1A ). In non-infected, parental MSCs, no IL-1Ra protein was detected. The IL-1Ra protein production per 10 4 cells was similar irrespective of the initial seeding density ( Figure 1B) .
In 48 h, nonstimulated cells produced approximately 1 ng/ml IL-1Ra
protein, and protein concentration was increased to approximately 4 ng/ml in cells stimulated with 10 ng/ml TNFα ( Figure 1B ).
In the next step, we analysed the repeated inducibility of IL-1Ra
expression from MSC/IL-1Ra cells. However, use of the same experimental set-up as that employed in our previous work (48 h of induction followed by 48 h of off-stimulation) 49 was not sufficient to bring the IL- Protein levels returned to baseline at day 6 after cytokine withdrawal ( Figure 2B ). Therefore, 6 days without cytokine stimulation was considered sufficient for the repeated stimulation experiment.
Finally, MSC/IL-1Ra cells were repeatedly stimulated with 10 ng/ml TNFα (stimulation for 48 h -144 h withdrawal of cytokinesecond stimulation for 48 h -second 144 h withdrawal of cytokine).
After the first stimulation, the IL-1Ra protein levels were increased six-to seven-fold followed by regress to IL-1Ra protein basal levels after 6 days of cultivation without TNFα ( Figure 2C ). Repeated stimulation also yielded a statistically significant three-fold increase in IL-1Ra protein production. Another 6 days without the cytokine stimulus resulted in IL-1Ra protein basal levels again ( Figure 2C ).
| 2D osteoarthritis in vitro model
In the 2D OA in vitro model, the expression pattern of ten OA-related genes (IL-1β, IL-6, IL-8, TNFα, MMP1, MMP3, MMP13, COL2A1,
ACAN, PTGES) of equine chondrocytes was analysed after IL-1β or
TNFα stimulation (Figure 3 ; see also Supporting information, Figure   S1 ). Compared to nontreated cells, mRNA expression of ACAN and COL2A1 was statistically significant decreased after both IL-1β or TNFα treatment, with a higher cytokine concentration and longer stimulation producing stronger effects. IL-6, IL-8, MMP1 and MMP13 mRNA levels were significantly increased upon cytokine treatment, with the strongest effects being observed after 24 h of stimulation.
Only a marginal increase of mRNA levels was observed in the case of PTGES, with changes in IL-1β, TNFα, and MMP3 mRNA levels being less obvious and inconsistent (see Supporting information, Figure S1 ).
Based on these observations, analysis of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13 mRNA levels and treatment with the respective cytokine(s) (10 ng/ml) was chosen for further experiments to monitor osteoarthritic changes in further experiments using OA in vitro models.
| Application of conditioned medium produced from MSC/IL-1Ra cells
To evaluate the biological activity of the IL-1Ra protein produced by the genetically modified MSCs, conditioned medium from these cells was Based on these results, 24 h of cytokine treatment was considered to be sufficient for OA induction in the 3D in vitro model.
| Co-cultivation of MSC/IL-1Ra cells with osteoarthritic chondrocytes
To model a therapeutic approach, OA-induced chondrocyte spheroids were co-cultured with MSC/IL-1Ra cells in the presence of proinflammatory cytokines (IL-1β, TNFα or a combination of both).
Expression levels of ACAN, COL2A1, IL-6, IL-8, MMP1 and MMP13
were compared with those of osteoarthritic chondrocytes grown in the absence of MSC/IL-1Ra cells ( Figure 6 ). The mRNA levels of ACAN and COL2A1 genes were significantly increased. A significant To analyse repeated transgene inducibility, cells were stimulated with 10 ng/ml TNFα for 48 h (first increase) and subsequently kept for another 144 h in standard medium (first decrease). The same stimulation regime was repeated afterwards (second increase and second decrease). The results (*) are considered significant with a lower confidence limit set greater than 1. Data show mean values; whiskers represent 95% confidence intervals decrease in IL-6, MMP1 and MMP13 expression levels was observed in co-cultured chondrocytes, whereas the changes in IL-8 mRNA levels
were less obvious and inconsistent. These effects were most distinct after OA induction with IL-1β and less prominent after treatment with
TNFα and the combination of IL-1β and TNFα.
| DISCUSSION
As a result of the limited self-renewal capacity of adult articular cartilage, cartilage defects and osteoarthritis lead to intense investigation on clinically applicable cartilage regenerating techniques. 65 MSCs represent an interesting cell source for cartilage repair because of their multilevel action (mostly paracrine activity, organelle and molecule transfer via tunnelling nanotubes, exosome and microvesicle transfer of molecules, as well as marginally also differentiation into replacement cell type) [66] [67] [68] and several preclincial and clinical trials have provided initial evidence of their efficacy and safety in the treatment of OA. 69, 70 However, MSCs have a tendency to undergo hypertrophic differentiaion and, when exposed to an inflammatory environment, they show a reduced chondrogenic differentiation capacity. [71] [72] [73] [74] Hence intra-articular application of MSCs has not yet achieved full restoration of hyaline cartilage. Employing the gene therapy concept to increase cartilage regeneration by expression of specific genes (e.g. anti-inflammatory cytokines, growth and transcription factors) represents another promising therapeutic strategy. 75 Combining cellular therapy using MSCs with gene transfer can combine the advantages of both innovating strategies and might help to overcome challenges that arise from using naïve MSCs. However, when using gene transfer techniques resulting in host genome Transgene expression was also detected in nonstimulated MSC/ IL-1Ra cells as a result of the presence of the minimal CMV promoter sequence within the inducible promoter, which is in agreement with our previous observations, 49 as well as with the observations of other studies. 84 The concentration of IL-1Ra protein produced from nonstimulated MSC/IL-1Ra cells (1.2 ng/ml/10 000 cells/48 h) is within the range of IL-1Ra levels in autologous conditioned serum. 39, 85 The use of tightly regulated inducible promoters such as those described recently by Mohamed et al. 50 might increase the specificity of expression.
Surprisingly, the decrease in IL-1Ra expression in MSC/IL-1Ra cells after TNFα withdrawal was three times slower (both on mRNA and protein levels) than the drop in luciferase expression previously observed in MSC/Luc cells, 49 probably as a result of the short half-life FIGURE 4 Conditioned medium of MSC/IL-1Ra cells blocks OA onset in cytokine treated equine chondrocytes. Cytokine-free conditioned medium from TNFα-stimulated (s) or nonstimulated (n.s.) MSCs or MSC/IL-1Ra cells was transferred onto equine chondrocytes grown in a monolayer and OA changes were induced by concomitant application of 10 ng/ml IL-1β. After 24 h, mRNA levels of aggrecan, collagen IIA1, interleukin-6, interleukin-8, matrix metalloproteinase-1 and matrix metalloproteinase-13 were measured using RT-qPCR. Chondrocytes cultured in normal medium containing IL-1β for OA induction were used as controls and mRNA levels obtained in these cells were arbitrary set to 1. Relative changes in gene expression in conditioned medium-treated chondrocytes are shown. Lower confidence limits greater than 1 and upper confidence limits less than 1 were assumed as statistically significant (*). Data show mean values; whiskers represent 95% confidence intervals of luciferase of less than 4 h. 86 Repeated stimulation of IL-1Ra production was possible, although IL-1Ra levels after the second stimulation were reduced to 50% compared to the first one. This is in accordance with our observations using luciferase expressing MSCs. 
FIGURE 5
Changes in OA-related gene expression in the 3D osteoarthritis in vitro model. Equine chondrocytes grown in spheroids were treated with 10 ng/ml IL-1β or TNFα, or a combination of both, for 24, 48 and 72 h. The mRNA levels of aggrecan, collagen IIA1, interleukin-6, interleukin-8, matrix metalloproteinase-1 and matrix metalloproteinase-13 were measured using RT-qPCR. Relative changes in mRNA levels of cytokinetreated chondrocytes are shown compared to nontreated chondrocytes arbitrary set to 1. Lower confidence limits greater than 1 and upper confidence limits less than 1 were assumed as statistically significant (*). Data show mean values; whiskers represent 95% confidence intervals instead, the contrary effect was observed, because chondrocytes treated with conditioned medium from stimulated and nonstimulated, nontransduced MSC revealed up-regulation of IL-6, IL-8 and MMP1, as well as down-regulation of COL2A1 genes. These observations were fairly unexpected because it is known that MSCs secrete factors inhibiting inflammatory processes 94 and a protective effect of MSC co-cultivated with IL-1β-treated chondrocytes in a rat osteoarthritic model was reported recently. 95 We are aware that these expression changes are influenced by several parameters that are closely related to the experimental set-up (e.g. co-cultivation versus conditioned medium, timing and duration of cytokine treatment, cell cultivation and harvesting time for RNA analysis), which might differ among the research groups and publications. Therefore, any direct comparison might be difficult. Co-cultivation of MSC/IL-1Ra cells with osteoarthritic spheroids alleviated the severity of osteoarthritic changes and this effect was most distinct after OA induction with IL-1β. This is not surprising because IL-1β is one of the key arthritogenic triggers and is much more potent than TNFα with respect to inducing cartilage destruction. 15 In conclusion, we could repeatedly induce transgene expression via cytokine stimulation of MSC/IL-1Ra cells. The IL-1Ra that was produced was biological active. Furthermore, we were able to demonstrate the protective ability of the IL-1Ra protein in an in vitro OA model analysing the genes responsible for extracellular matrix proteins, the enzymes for matrix degradation and pro-inflammatory cytokines.
Future studies are planned that focus on an improvement of tight regulation of transgene expression and an assessment of the therapeutic potential of the described system in a relevant in vivo model.
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